This company listing is no longer active
HCM N Stock Overview
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
HUTCHMED (China) Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£819.63 |
| 52 Week High | UK£0 |
| 52 Week Low | UK£0 |
| Beta | 0.88 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 0% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -2.89% |
Recent News & Updates
Recent updates
Shareholder Returns
| HCM N | MX Pharmaceuticals | MX Market | |
|---|---|---|---|
| 7D | 0% | 0.7% | -0.6% |
| 1Y | 0% | -22.3% | -9.7% |
Return vs Industry: HCM N exceeded the MX Pharmaceuticals industry which returned -15% over the past year.
Return vs Market: HCM N underperformed the MX Market which returned 3.7% over the past year.
Price Volatility
| HCM N volatility | |
|---|---|
| HCM N Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in MX Market | 7.1% |
| 10% least volatile stocks in MX Market | 2.8% |
Stable Share Price: HCM N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine HCM N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 1,280 | Wei-Guo Su | www.hutch-med.com |
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3’-kinase delta).
HUTCHMED (China) Limited Fundamentals Summary
| HCM N fundamental statistics | |
|---|---|
| Market cap | Mex$34.76b |
| Earnings (TTM) | -Mex$6.23b |
| Revenue (TTM) | Mex$7.37b |
4.7x
P/S Ratio-5.6x
P/E RatioIs HCM N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HCM N income statement (TTM) | |
|---|---|
| Revenue | US$426.41m |
| Cost of Revenue | US$698.00m |
| Gross Profit | -US$271.59m |
| Other Expenses | US$89.25m |
| Earnings | -US$360.83m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.43 |
| Gross Margin | -63.69% |
| Net Profit Margin | -84.62% |
| Debt/Equity Ratio | 2.8% |
How did HCM N perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/06/13 21:39 |
| End of Day Share Price | 2023/03/16 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
HUTCHMED (China) Limited is covered by 45 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| John Newman | Canaccord Genuity |
| Adam McCarter | Cavendish |